Jax DiEugenio

FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma

October 9th 2025

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma

October 9th 2025

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ Breast Cancer

October 9th 2025

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

Dr Dreyling on the Rationale for Adding Acalabrutinib to BR in High-Risk MCL

October 8th 2025

Martin Dreyling, MD, discusses why adding acalabrutinib to bendamustine plus rituximab may benefit patients with pretreated, high-risk MCL.

Dr Saad on the Rationale for the PEACE-3 Trial in mCRPC With Bone-Predominant Disease

October 8th 2025

Fred Saad, MD, discusses the rationale behind the long-term safety analysis for radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer with bone-predominant disease.

FDA Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma

October 8th 2025

The FDA approved cemiplimab-rwlc for the adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

Inside the Most Anticipated Genitourinary Cancer Abstracts: What to Watch at ESMO 2025

October 8th 2025

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia

October 8th 2025

The FDA has issued a CRL for dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

Dr Sampath on the Safety of Consolidative Radiotherapy Plus Osimertinib in Advanced EGFR-Mutant NSCLC

October 7th 2025

Sagus Sampath, MD, discusses the safety profile of consolidative radiotherapy administered in conjunction with osimertinib in advanced EGFR-mutant NSCLC

Dr Qiu on the Efficacy and Safety of Eque-Cel in Relapsed/Refractory Multiple Myeloma

October 7th 2025

Luqui Qiu, MD, discusses the efficacy and safety of eque-cel in patients with relapsed or refractory multiple myeloma.

NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ NSCLC

October 7th 2025

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer

October 7th 2025

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell Lymphoma

October 7th 2025

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

Linvoseltamab Demonstrates Potential for Early Intervention in High-Risk Smoldering Multiple Myeloma

October 7th 2025

Paula Rodriguez-Otero, MD, discusses linvoseltamab’s potential role in the management of high-risk smoldering myeloma.

FDA Approval of Intravesical Mitomycin in NMIBC Follows ODAC Debate on Need for Randomized Data

October 7th 2025

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma

October 6th 2025

Andrew Yee, MD, discusses lenalidomide plus ixazomib,​ dexamethasone, and daratumumab in newly diagnosed multiple myeloma.

Dr Van Tine on Investigating Olaparib Plus Temozolomide vs Investigator’s Choice of Therapy in Advanced Uterine Leiomyosarcoma

October 6th 2025

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Dr LeVee on Limitations of the ASCENT-04 Trial of Sacituzumab Govitecan Plus Pembrolizumab in TNBC

October 6th 2025

Alexis LeVee, MD, discusses the clinical implications of the ASCENT-04 trial data for patients with TNBC who relapse following prior PD-1 or PD-L1 therapy.

Dr Runcie on the Mechanism of Action of XmAb30819 in ccRCC

October 6th 2025

Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL

October 6th 2025

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.